| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8809196 | Archives de Pédiatrie | 2018 | 6 Pages |
Abstract
Palivizumab administration in France generally conformed with TC guidelines, but could be further improved for infants born at 27-32 weeks' gestation without bronchopulmonary dysplasia.
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
H. Torchin, J. Rousseau, L. Marchand-Martin, P. Truffert, P.-H. Jarreau, P.-Y. Ancel,